Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Cardiac Science CORP (CSCX)
|
Add to portfolio |
|
|
|
| Price: |
$2.27
| | Metrics |
| OS: |
23.4
|
M
| |
-146
|
% ROE
|
| Market cap: |
$53.1
|
M
| |
-1621
|
% ROIC
|
|
Net cash:
|
$7
|
M
| |
$0.30
|
per share
|
|
EV:
|
$46.1
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($34.1)
|
M
| |
|
|
|
EBIT
|
($40.5)
|
M
| |
|
|
| EPS |
($1.77)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-09 | Dec-31-08 | Dec-31-07 | Dec-31-06 | Dec-31-05 | Dec-31-04 | Dec-31-03 |
| Revenues | 156.8 | 206.2 | 182.1 | 155.4 | 106.7 | 89.6 | 84.4 |
| Revenue growth | -23.9% | 13.2% | 17.2% | 45.7% | 19.0% | 6.2% | |
| Cost of goods sold | 101.7 | 103.9 | 93.7 | 82.2 | 59.8 | 50.3 | 51.1 |
| Gross profit | 55.2 | 102.3 | 88.4 | 73.2 | 46.9 | 39.3 | 33.3 |
| Gross margin | 35.2% | 49.6% | 48.5% | 47.1% | 43.9% | 43.9% | 39.4% |
| Sales and marketing | 48.0 | 50.7 | 46.2 | 40.0 | 25.0 | 18.4 | 17.7 |
| Research and development | 15.0 | 16.4 | 13.0 | 11.7 | 9.4 | 7.4 | 8.1 |
| General and administrative | 26.1 | 22.4 | 19.2 | 19.1 | 14.2 | 8.3 | |
| EBIT | -33.9 | 12.7 | 12.2 | -1.4 | -2.6 | 5.2 | -0.2 |
| EBIT margin | -21.6% | 6.2% | 6.7% | -0.9% | -2.4% | 5.8% | -0.3% |
| Pre-tax income | -33.8 | -93.8 | 13.4 | -0.6 | -1.3 | 6.1 | 0.0 |
| Income taxes | 42.5 | 4.1 | 4.9 | -0.6 | 0.0 | -8.9 | -0.1 |
| Tax rate | | | 36.7% | 99.2% | 2.4% | | |
| Net income | -77.0 | -98.4 | 8.5 | -0.1 | -1.3 | 15.0 | -1.8 |
| Net margin | -49.1% | -47.7% | 4.7% | 0.0% | -1.2% | 16.7% | -2.1% |
| |
| Diluted EPS | ($3.31) | ($4.30) | $0.37 | $0.00 | ($0.09) | $1.39 | ($0.19) |
| Shares outstanding (diluted) | 23.3 | 22.9 | 23.2 | 22.6 | 14.7 | 10.8 | 9.4 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|